Barrier files for IPO

Published: 9-Feb-2004


Barrier Therapeutics, from Princeton, NJ, US has filed for an initial public offering of shares of its common stock.

The company is a biopharmaceutical company focused on the discovery, development and commercialisation of pharmaceutical products in the field of dermatology.

The Company has eight product candidates in various stages of clinical development. The four most advanced product candidates, which are in or entering Phase III clinical trials, are under development for the treatment of seborrheic dermatitis, Candida-associated diaper dermatitis, fungal infections, including vaginal candidiasis and tinea pedis, and congenital ichthyosis.

The Company has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis, fungal infections, allergies and dermatitis.

Underwriters

The managing underwriter of the offering will be Morgan Stanley, acting as book-running manager, with Banc of America Securities LLC and J.P. Morgan Securities Inc. as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined. A copy of the preliminary prospectus relating to the offering may be obtained, when available, from Morgan Stanley's prospectus department, located at 1585 Broadway, New York, NY 10036-8200. T +1 212 761 6775.

You may also like